Loading peptide profile…
Loading peptide profile…
Longevity Category
THE RETINA REGENERATOR
Retinal Peptide Complex A-17
Retinalamin is a mixture of peptide fractions studied for retinal disease. A Russian randomized study examined patients with open-angle glaucoma and controlled eye pressure. It is not FDA approved.
Those with age-related macular degeneration · People with diabetic retinopathy · Anyone with retinitis pigmentosa · Those recovering from retinal damage · People wanting to protect long-term vision
Not FDA approved, research use onlyHow we review these guides15 research sources
A 180-patient study reported changes in visual field measures. Visual acuity did not change significantly, and several structural measures remained stable.
Improves blood flow to retinal tissue
Stabilizes photoreceptor membranes
Promotes neuroprotective factors in retina
No. This profile records Retinalamin as not FDA approved and for research use only. Review the regulatory and source details on this page for the current context.
This guide links to 15 curated or current research sources. Inspect the research section and the citations beneath the research answers for their supporting sources.
Review the Retinalamin research sourcesWe don't list specific side effects for Retinalamin.
Retinalamin has an editorial safety grade of A (Excellent Safety). Human clinical studies exist, but the cited glaucoma abstract gives no detailed adverse event results. The manufacturer lists possible allergic reactions; long-term risks remain incompletely characterized. Safety depends on dose, sourcing, health history and medical supervision, so this page does not call it safe for personal use.
Retinalamin is described as a complex of peptides isolated from cattle retinas. It is also called a retinal polypeptide and a polypeptide preparation isolated from the retina, and it is described as a peptide bioregulator isolated from cattle retina. In a case report, Retinalamin, described as a peptide-based drug, was used in a patient with newly diagnosed glaucoma, and intraocular pressure was therapeutically normalized. In laboratory studies, Retinalamin was tested on multipotent ectodermal cells of the early gastrula of Xenopus laevis (African clawed frog embryos). Retinalamin was also studied, alongside the synthetic peptide Epithalon, for its effect on proliferative activity of retinal and pigmented epithelial cells.
In a clinical trial of patients with stage II primary open-angle glaucoma (POAG), Retinalamin therapy brought lacrimal fluid BDNF and NSE concentrations down to control-group values. In stage III patients, NSE content remained high after Retinalamin therapy. Lacrimal fluid BDNF and NSE were measured by enzyme immunoassay (ELISA) before and after treatment.
Market evidence
We have not assessed certificate coverage for Retinalamin yet. Research on this page describes the molecule. Vendor certificates concern particular market samples or batches; they do not change the research evidence or establish clinical safety, sterility, or suitability for use.
The clinic network
Request a free connection to a peptide clinic, by telehealth or in person. A licensed clinician decides whether any treatment is right for you. What peptide therapy involves
An EDR tripeptide studied in nerve cell models
from $1.25/mg · 125 vendorsNº 003 / 006An animal liver peptide mixture in developer reports
Full profileNº 005 / 006An animal eye peptide mixture in developer reports
Full profileNº 006 / 006Mitochondria-targeting peptide, FDA-approved for Barth syndrome
from $1.35/mg · 199 vendorsNº 004 / 006An animal bone marrow peptide mixture in developer reports
Full profileNº 001 / 006An animal parathyroid peptide mixture in developer reports
Full profileNº 002 / 006